Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (IgG(L)-scFv) is formed by an IgG and two scFv moieties. The scFv fragments from an anti-CD89 antibody are fused to the C terminus of an anti-EGFR IgG light (L) chains, or vice versa. It is a type of appended IgGs, which is bispecific and tetravalent (2+2 antigen-binding valency). This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.